BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 11848550)

  • 1. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
    Filella X; Alcover J; Corral JM; Molina R; Beardo P; Ballesta AM
    Anticancer Res; 2001; 21(5):3717-20. PubMed ID: 11848550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
    Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
    Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of proprostate-specific antigen in the diagnosis of prostate cancer.
    Filella X; Alcover J; Molina R; Luque P; Corral JM; Augé JM; Coca F
    Anticancer Res; 2007; 27(1B):607-10. PubMed ID: 17348449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer.
    Mitchell ID; Croal BL; Dickie A; Cohen NP; Ross I
    J Urol; 2001 May; 165(5):1549-53. PubMed ID: 11342915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer.
    Froehner M; Hakenberg OW; Koch R; Schmidt U; Meye A; Wirth MP
    Urol Int; 2006; 76(1):27-30. PubMed ID: 16401917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer.
    Van Cangh PJ; De Nayer P; Sauvage P; Tombal B; Elsen M; Lorge F; Opsomer R; Wese FX
    Prostate Suppl; 1996; 7():30-4. PubMed ID: 8950361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer.
    Romppanen J; Haapalainen T; Punnonen K; Penttilä I
    Anticancer Res; 2002; 22(1A):415-20. PubMed ID: 12017325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
    Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
    Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.
    Brawer MK; Cheli CD; Neaman IE; Goldblatt J; Smith C; Schwartz MK; Bruzek DJ; Morris DL; Sokoll LJ; Chan DW; Yeung KK; Partin AW; Allard WJ
    J Urol; 2000 May; 163(5):1476-80. PubMed ID: 10751861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of free/total prostate specific antigen in the early diagnosis of prostate cancer (study of 105 patients)].
    de la Taille A; Houlgatte A; Houdelette P; Berlizot P; Ramirez J; Ricordel I
    Prog Urol; 1997 Apr; 7(2):240-5. PubMed ID: 9264766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ratio of free to total prostate specific antigen: an advantageous addition in the differential diagnosis of benign hyperplasia and cancer of the prostate?
    Reiter W; Stieber P; Schmeller N; Nagel D; Jansen HM; Schambeck C; Fabricius PG; Pahl H; Mattes M; Constabel H; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):2987-91. PubMed ID: 9329582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reference ranges for the concentrations of total and complexed plasma prostate-specific antigen and their ratio in patients with benign prostate hyperplasia.
    España F; Martínez M; Royo M; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF
    Eur Urol; 1997; 32(3):268-72. PubMed ID: 9358211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA
    Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of free to total prostate specific antigen ratio in serum in the diagnosis of prostatic enlargement.
    Bhuiyan AK; Kibria SA; Subhan SS
    Bangladesh Med Res Counc Bull; 2004 Aug; 30(2):51-9. PubMed ID: 15813483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The percentage of free prostate specific antigen used in detecting prostate cancer].
    Yang L; Fang Z; Song J; Deng S
    Zhonghua Wai Ke Za Zhi; 1999 Jan; 37(1):47-9. PubMed ID: 11829778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
    Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
    Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical aspects related to the interpretation of the free-to-total PSA-ratio.
    Wolff JM; Stocker G; Borchers H; Haubeck H; Greiling H; Jakse G
    Anticancer Res; 1999; 19(4A):2633-6. PubMed ID: 10470208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-dimensional electrophoresis of prostate-specific antigen in sera of men with prostate cancer or benign prostate hyperplasia.
    Charrier JP; Tournel C; Michel S; Dalbon P; Jolivet M
    Electrophoresis; 1999; 20(4-5):1075-81. PubMed ID: 10344287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha 1-antichymotrypsin-PSA (ACT-PSA): a useful marker in the differential diagnosis of benign hyperplasia and cancer of the prostate?
    Reiter W; Stieber P; Schmeller N; Nagel D; Fateh-Moghadam A
    Anticancer Res; 1997; 17(6D):4767-70. PubMed ID: 9494604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
    Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.